Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
Machover
D
D
Gastiaburu
J
J
Delgado
M
M
Goldschmidt
E
E
Hulhoven
R
R
Benavides
M
M
Lotz
J P
JP
Misset
J L
JL
de Vassal
F
F
Tapiero
H
H
D015250:Aclarubicin; D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin